Blood-borne biomarkers: CT-DNA ushers in a new era of cancer detection
Abstract
Circulating tumor DNA, also called ctDNA, is gaining popularity as a valuable tool for monitoring cancer through non-invasive methods. This review seeks to offer a comprehensive overview of ctDNA, encompassing its biological basis, detection technologies, clinical applications, and challenges. ctDNA originates from tumor cells that undergo apoptosis and necrosis, and contain cancer-specific genomic and epigenomic alterations. Sensitive methodologies leveraging sequencing, digital PCR, and enzymatic assays enable the analysis of mutations, methylation patterns, and copy number variations. ctDNA facilitates early diagnosis, minimal residual disease tracking, therapeutic monitoring, detection of emergent resistance mutations, and prognostic estimates across diverse cancer types. Ongoing trials aim to validate ctDNA's clinical utility and determine whether ctDNA-guided early interventions enhance outcomes. Detection using ctDNA analysis faces some challenges, including specificity, sensitivity, and result interpretation. Research is needed towards advancing the detection technology, development of standards, and establishing clinical validity. Overall, the analysis of plasma ctDNA provides a powerful and minimally invasive avenue for understanding tumor dynamics in real-time to enable personalized therapeutic approaches, monitoring, and potentially early cancer detection.
Keywords:
Circulating tumor DNA (ctDNA), Liquid biopsy, Non-invasive diagnostics, Tumor genomics, Cancer biomarkers, Personalized medicine, Early cancer detection, DNA sequencing, Mutation analysis, DNA methylation, Cancer prognosis, Precision oncologyDOI
https://doi.org/10.25004/IJPSDR.2024.160518References
Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016 Jul 7;7(30):48832. Available from: doi.org/10.18632/oncotarget.9453
Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. Critical reviews in oncology/hematology. 2020 Nov 1;155:103109. Available from: doi.org/10.1016/j.critrevonc.2020.103109
Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Molecular Cancer Research. 2016 Oct 1;14(10):898-908. Available from: doi.org/10.1158/1541-7786.MCR-16-0044
Wang R, Li X, Zhang H, Wang K, He J. Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker. Oncotarget. 2017 Sep 9;8(43):75742. Available from: doi.org/10.18632/oncotarget.20608
Yan YY, Guo QR, Wang FH, Adhikari R, Zhu ZY, Zhang HY, Zhou WM, Yu H, Li JQ, Zhang JY. Cell-free DNA: hope and potential application in cancer. Frontiers in cell and developmental biology. 2021 Feb 22;9:639233. Available from: doi.org/10.3389/fcell.2021.639233
Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017 Apr;17(4):223-38. Available from: doi.org/10.17863/CAM.7352
Grabuschnig S, Bronkhorst AJ, Holdenrieder S, Rosales Rodriguez I, Schliep KP, Schwendenwein D, Ungerer V, Sensen CW. Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms. International journal of molecular sciences. 2020 Oct 29;21(21):8062. Available from: doi.org/10.3390/ijms21218062
Angeles AK, Janke F, Bauer S, Christopoulos P, Riediger AL, Sültmann H. Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer. Cancers. 2021 Nov 10;13(22):5615. Available from: doi.org/10.3390/cancers13225615
Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O’Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA oncology. 2016 Aug 1;2(8):1014-22. Available from: doi.org/10.1001/jamaoncol.2016.0173
Kim H, Park KU. Clinical circulating tumor DNA testing for precision oncology. Cancer Research and Treatment: Official Journal of Korean Cancer Association. 2023 Mar 13;55(2):351-66. Available from: doi.org/10.4143/crt.2022.1026
Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van’t Veer LJ, Magbanua MJ. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Molecular cancer. 2023 Jan 21;22(1):15. Available from: doi.org/10.1186/s12943-022-01710-w
Wang W, Kong P, Ma G, Li L, Zhu J, Xia T, Xie H, Zhou W, Wang S. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. Oncotarget. 2017 Jun 6;8(26):43180. Available from: doi.org/10.18632/oncotarget.17858
Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer biology & therapy. 2019 Aug 3;20(8):1057-67. Available from: doi.org/10.1080/15384047.2019.1598759
Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase–mediated changes in LDL density. Circulation. 1999 Apr 20;99(15):1959-64. Available from: doi.org/10.1161/01.CIR.99.15.1959
Bittla P, Kaur S, Sojitra V, Zahra A, Hutchinson J, Folawemi O, Khan S. Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review. Cureus. 2023 Sep;15(9). Available from: doi.org/10.7759/cureus.45784
Goodwill AG, Dick GM, Kiel AM, Tune JD. Regulation of coronary blood flow. Comprehensive Physiology. 2017 Mar 3;7(2):321. Available from: doi.org/10.1016/0033-0620(75)90001-8
Lv X, Zhao M, Yi Y, Zhang L, Guan Y, Liu T, Yang L, Chen R, Ma J, Yi X. Detection of rare mutations in CtDNA using next generation sequencing. JoVE (Journal of Visualized Experiments). 2017 Aug 24(126):e56342. Available from: doi.org/10.3791/56342-v
Wen X, Pu H, Liu Q, Guo Z, Luo D. Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques. Cancers. 2022 Dec 7;14(24):6025. Available from: doi.org/10.3390/cancers14246025
Santonja A, Cooper WN, Eldridge MD, Edwards PA, Morris JA, Edwards AR, Zhao H, Heider K, Couturier DL, Vijayaraghavan A, Mennea P. Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer. EMBO molecular medicine. 2023 Jun 7;15(6):e16505. Available from: doi.org/10.15252/emmm.202216505
Duffy MJ, Crown J. Circulating tumor DNA as a biomarker for monitoring patients with solid cancers: comparison with standard protein biomarkers. Clinical Chemistry. 2022 Nov 3;68(11):1381-90. Available from: doi.org/10.1093/clinchem/hvac121
Garcia J, Kamps-Hughes N, Geiguer F, Couraud S, Sarver B, Payen L, Ionescu-Zanetti C. Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools. Scientific reports. 2021 May 24;11(1):10761. Available from: doi.org/10.1038/s41598-021-89592-8
Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Human genomics. 2019 Aug 1;13(1):34. Available from: doi.org/10.1186/s40246-019-0220-8
Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science translational medicine. 2016 Jul 6;8(346):346ra92. Available from: doi.org/10.1126/scitranslmed.aaf6219
Nygaard AD, Holdgaard PC, Spindler KL, Pallisgaard N, Jakobsen A. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. British journal of cancer. 2014 Jan;110(2):363-8. Available from: doi.org/10.1038/bjc.2013.705
Catarino R, Coelho A, Araújo A, Gomes M, Nogueira A, Lopes C, Medeiros R. Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PloS one. 2012 Jun 12;7(6):e38559. Available from: doi.org/10.1371/journal.pone.0038559
Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, Hosking K. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS medicine. 2016 Dec 20;13(12):e1002198. Available from: doi.org/10.1371/journal.pmed.1002198
Mandel P. Les acides nucleiques du plasma sanguin chez 1 homme. CR Seances Soc Biol Fil. 1948;142:241-3.
Schreuer M, Meersseman G, Van Den Herrewegen S, Jansen Y, Chevolet I, Bott A, Wilgenhof S, Seremet T, Jacobs B, Buyl R, Maertens G. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Journal of translational medicine. 2016 Dec;14:1-1. Available from: doi.org/10.1186/s12967-016-0852-6
Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. Journal for immunotherapy of cancer. 2023;11(6). Available from: doi.org/10.1136/jitc-2022-006284
Zhao J, Reuther J, Scozzaro K, Hawley M, Metzger E, Emery M, Chen I, Barbosa M, Johnson L, O’Connor A, Washburn M. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors. Molecular Diagnosis & Therapy. 2023 Nov;27(6):753-68. Available from: doi.org/10.1007/s40291-023-00670-1
Chidharla A, Rapoport E, Agarwal K, Madala S, Linares B, Sun W, Chakrabarti S, Kasi A. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis. International journal of molecular sciences. 2023 Jun 16;24(12):10230. Available from: doi.org/10.3390/ijms241210230
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW. Circulating mutant DNA to assess tumor dynamics. Nature medicine. 2008 Sep;14(9):985-90. Available from: doi.org/10.1038/nm.1789
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, Hadfield J. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Science translational medicine. 2012 May 30;4(136):136ra68-. Available from: doi.org/10.1126/scitranslmed.3003726
Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, Singh H, Philip R, Pazdur R, Beaver JA. Regulatory implications of ctDNA in immuno-oncology for solid tumors. Journal for ImmunoTherapy of Cancer. 2023;11(2). Available from: doi.org/10.1136/jitc-2022-005344
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. Journal of Clinical Oncology. 2023 Apr 20;41(12):2238-47. Available from: doi.org/10.1200/JCO.22.01725
Honoré N, Galot R, van Marcke C, Limaye N, Machiels JP. Liquid biopsy to detect minimal residual disease: methodology and impact. Cancers. 2021 Oct 26;13(21):5364. Available from: doi.org/10.3390/cancers13215364
Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC medicine. 2018 Dec;16:1-0. Available from: doi.org/10.1186/s12916-018-1157-9
Mannelli C. Tissue vs liquid biopsies for cancer detection: ethical issues. Journal of bioethical inquiry. 2019 Dec;16(4):551-7. Available from: doi.org/10.1007/s11673-019-09944-y
Heitzer E, Haque IS, Roberts CE, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nature Reviews Genetics. 2019 Feb;20(2):71-88. Available from: doi.org/10.1038/s41576-018-0071-5
Kilgour E, Rothwell DG, Brady G, Dive C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer cell. 2020 Apr 13;37(4):485-95. Available from: doi.org/10.1016/j.ccell.2020.03.012
Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA: a cancer journal for clinicians. 2021 Mar;71(2):176-90. Available from: doi.org/10.3322/caac.21650
Duffy MJ, Crown J. Use of circulating tumour DNA (ctDNA) for measurement of therapy predictive biomarkers in patients with cancer. Journal of Personalized Medicine. 2022 Jan 13;12(1):99. Available from: doi.org/10.3390/jpm12010099
Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. The Journal of clinical investigation. 2022 Jun 15;132(12). Available from: doi.org/10.1172/JCI154941
Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, Powles T, Li BT, Pusztai L, Aushev VN, Kalashnikova E. Impact of circulating tumor DNA–based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors. JCO Precision Oncology. 2022 Mar;6:e2100181. Available from: doi.org/10.1200/PO.21.00181
Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. British journal of cancer. 2021 Jan 19;124(2):345-58. Available from: doi.org/10.1038/s41416-020-01047-5
Oncology Center of Excellence, U.S. Food And Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH) [Internet] -May 2022. Use of circulating tumor deoxyribonucleic acid for Early-Stage solid Tumor drug development; Draft guidance for industry. [Cited 20th Feb 2024]. Available From: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-draft-guidance.
Published
Abstract Display: 344 
PDF Downloads: 319 How to Cite
Issue
Section
Copyright (c) 2024 Sanket Palve, Yash Bhardwaj, Jayesh Dusane, Pavankumar Wankhade
This work is licensed under a Creative Commons Attribution 4.0 International License.
